Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Liposome bupivacaine+ bupivacaine · 1 trial · 1 indication
Pain rating (NRS) at rest and with movement
| Arm | Type | Description |
|---|---|---|
| Single mixture LB & bupivacaine | EXPERIMENTAL | A single mixture of liposome bupivacaine 1.3% (5 mL) + bupivacaine 0.5% (2.5 mL) injected into the median and ulnar nerves |
| Bupivacaine alone | ACTIVE_COMPARATOR | Bupivacaine 0.5% (7.5 mL) injected into the median and ulnar nerves |
| Name | Type | Description |
|---|---|---|
| Liposome bupivacaine + bupivacaine | DRUG | - |
Inclusion Criteria: * Male or female, at least 18 years and max 85 years of age at screening * Scheduled to undergo Dupuytren's contracture release * American Society of Anesthesiologists (ASA) physical status I, II or III * Able to demonstrate sensory function by exhibiting sensitivity to cold, pi...
Liposome bupivacaine is an investigational drug being studied for use in Hallux Valgus (Bunions) and Dupuytren's Contracture of the Hand (Viking's Disease). It is a small molecule being developed by Pacira BioSciences, Inc. for these indications.
Liposome bupivacaine is a small molecule. Its specific molecular target has not been disclosed in the available information.
Liposome bupivacaine is being developed by Pacira BioSciences, Inc., a company traded under the ticker symbol PCRX.
Liposome bupivacaine is in Phase 2 clinical development. It is investigational and has not been approved by regulatory authorities.
Liposome bupivacaine has been studied in two completed Phase 2 trials. NCT03106519 evaluated it for Dupuytren's Contracture of the Hand, and NCT03106545 evaluated it for Hallux Valgus (Bunions). Both trials were conducted in Belgium.
Liposome bupivacaine is a formulation of bupivacaine, but it is not the same as standard bupivacaine. The liposome formulation is designed to provide extended release of the drug.